Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer Aftimos, P., Maglakelidze, M., Glaudemans, A. M., Hamilton, E., Chap, L., de Vries, E., van Oordt, C., Jager, A., Dees, E., Cristofanilli, M., Pegram, M., Ulahannan, S., Neven, P., Bulat, I., Rai, R., Tao, W., Jain, S., Beelen, A. P., Sorrentino, J. A. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000618737700246